Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.
Pfizer, Inc., New York, NY, USA.
Curr Med Res Opin. 2024 Nov;40(11):1913-1920. doi: 10.1080/03007995.2024.2410930. Epub 2024 Oct 7.
To assess tablet utilization patterns and describe pre-treatment characteristics among new users of rimegepant.
Rimegepant is the only oral calcitonin gene-related peptide antagonist approved in the United States for both the acute and preventive treatment of migraine.
We conducted a retrospective cohort study of people with migraine who initiated treatment with rimegepant using two US commercial claims databases (MarketScan and Optum). Patients (≥18 years old) with migraine who newly initiated rimegepant were included. Patients were stratified into two groups representing acute (quantity = 8) and prevention (quantity = 15 or 16) use cohorts. Baseline characteristics and medication use history were assessed on index and during the 365-day pre-index period. Rimegepant utilization periods were calculated based on days supplied and varying approaches to define use periods. Tablet quantity per 30 days was reported separately for both acute and prevention cohorts.
In MarketScan, a total of 14,037 rimegepant users were identified; 11,195 (79.8%) in the acute group and 1,880 (13.4%) in the prevention group. Rimegepant utilization for acute use was 4.9 ± 2.1 tablets per 30 days and for preventive use was 13.1 ± 7.7 tablets per 30 days. There was high baseline prevalence of triptan contraindications, warnings, and high cardiovascular risk, with a combined 46.2% meeting one or more of these criteria. Acute medication overuse was also common (25.1%) prior to rimegepant initiation. Results were consistent in the Optum database.
Our analysis provides the first real-world data available on tablet utilization and characteristics of new users of rimegepant.
评估rimegepant 新使用者的片剂使用模式并描述治疗前特征。
rimegepant 是唯一在美国获批用于偏头痛急性和预防性治疗的口服降钙素基因相关肽拮抗剂。
我们使用美国两个商业索赔数据库（MarketScan 和 Optum）开展了一项新启用 rimegepant 治疗的偏头痛患者回顾性队列研究。纳入新启用 rimegepant 的偏头痛患者。患者分为两组，分别代表急性（数量=8）和预防（数量=15 或 16）用途队列。在指数日和前 365 天索引期评估基线特征和药物使用史。根据供应天数和不同方法计算 rimegepant 使用期。分别报告急性和预防队列的 30 天内片剂数量。
在 MarketScan 中，共确定了 14037 例 rimegepant 使用者；急性组 11195 例（79.8%），预防组 1880 例（13.4%）。急性用途的 rimegepant 使用率为 4.9±2.1 片/30 天，预防用途为 13.1±7.7 片/30 天。基线时存在高比例的曲坦禁忌证、警告和高心血管风险，有 46.2%的患者符合这些标准中的一项或多项。在启用 rimegepant 之前，急性药物过度使用也很常见（25.1%）。Optum 数据库中的结果一致。
我们的分析提供了 rimegepant 新使用者片剂使用和特征的首个真实世界数据。
